Vitasora Health Limited VHLUF
- Market cap
- —
- P/E
- —
Follow VHLUF
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.03 | 0.02 | 0.02 | 0.04 | 0.04 | 0.08 | 0.02 | 0.01 | 0.00 | 0.00 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 0.07 | 0.03 | 0.09 | 0.11 | 0.17 | 0.14 | 0.08 | 0.06 | 0.06 | 0.06 |
High Price
|
|||
| — | — | — | — | — | — | — | — | — | — | Employees | |||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 2 |
Revenue
|
|||
| 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 12.09% | 66.72% | 90.11% | 100.00% | 100.00% |
Gross Margin
|
|||
| 0 | 1 | (6) | (6) | (5) | (8) | (5) | (4) | (5) | (7) |
EBT
|
|||
| 100.00% | 100.00% | (888.71%) | (821.72%) | (328.99%) | (768.09%) | (850.30%) | (872.31%) | (686.45%) | (272.69%) |
EBT Margin
|
|||
| 0 | 0 | 0 | (6) | (5) | 0 | (5) | (4) | (5) | (7) |
Net Income
|
|||
| — | — | — | 0 | 0 | — | 0 | 0 | 0 | 0 |
Depreciation
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue/Sh
|
|||
| (0.01) | 0.00 | (0.01) | (0.01) | (0.01) | (0.01) | (0.01) | (0.01) | 0.00 | 0.00 |
Earnings/Sh
|
|||
| 0.00 | 0.00 | 0.00 | (0.01) | (0.01) | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 |
Cash Flow/Sh
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| 0.00 | 0.00 | 0.00 | (0.01) | (0.01) | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 |
Free CF/Sh
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 |
Book Value/Sh
|
|||
| 299 | 433 | 441 | 499 | 570 | 699 | 729 | 806 | 1,018 | 1,396 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PB Ratio
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | (0.02) | 0.00 | (0.02) |
EV/FCF
|
|||
| — | — | — | (5) | (3) | (5) | (6) | (3) | (4) | (6) |
Op' Cash Flow
|
|||
| — | — | — | 0 | 0 | 0 | 0 | 0 | — | — |
Capex
|
|||
| — | — | — | (5) | (3) | (6) | (6) | (3) | (4) | (6) |
FCF
|
|||
| — | — | (1) | (1) | 2 | 6 | 2 | 1 | 0 | 1 |
Working Cap'
|
|||
| — | — | — | 1 | 0 | — | — | — | 0 | — |
Total Debt
|
|||
| — | — | 0 | 0 | (2) | (6) | (1) | 0 | 0 | 0 |
Net Debt
|
|||
| — | — | (1) | (1) | 2 | 6 | 2 | 1 | 2 | 9 |
Sh' Equity
|
|||
| 0.00% | 0.00% | (686.16%) | (836.12%) | (254.84%) | (166.54%) | (97.52%) | (149.74%) | (150.78%) | (81.91%) |
ROA
|
|||
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (231.23%) | (528.83%) | (228.58%) | (44.24%) |
ROIC
|
|||
| 0.00% | 0.00% | 0.00% | 15.30% | (1,748.82%) | (225.03%) | (122.62%) | (283.90%) | (409.05%) | (116.56%) |
ROE
|
|||
Vitasora Health Limited (VHLUF) key facts
- Vitasora Health Limited’s revenue for fiscal 2025 (year ended June 2025) was AUD 2.4 million, up 252.3% from fiscal 2024.
- Vitasora Health Limited reported a net loss of AUD 6.5 million, or a loss of AUD 0.00 per share, for fiscal 2025.
- Return on equity was −116.6% and debt-to-equity 0.00.
Vitasora Health Limited (VHLUF) Latest News
6 May
Vitasora Health Limited (ASX:VHL) continues posting losses, with analysis projecting breakeven profitability in approximately 3 years assuming 39% annual revenue growth while slowing expense increases. Breakeven timeline projections shape expectations for financial turnaround and valuation multiples.
27 Nov
Vitasora Health Limited (ASX:VHL) is advancing towards profitability by implementing strategic initiatives aimed at enhancing operational efficiency and expanding its market presence. The company is focusing on optimizing its product offerings and improving customer engagement to drive revenue growth. Recent developments indicate a positive trajectory, with management expressing confidence in achieving financial targets in the near future. Investors are encouraged by the potential for increased market share and improved financial performance as Vitasora continues to refine its business model. Strategic initiatives aimed at profitability and market expansion are likely to significantly impact future performance.